DOI:

Comparison of EuroSCORE and EuroSCORE II in predicting short-term mortality in patients undergoing TAVI

Huczek Z.1, Rymuza B.1, Scibisz A.1, Kochman J.1, Wilimski R.2, Cichon R.2, Opolski G.1

Risk assesment in TAVI including valve-in-valve

Comparison of EuroSCORE and EuroSCORE II in predicting short-term mortality in patients undergoing TAVI

Aims: The logistic EuroSCORE was designed to estimate the risk of 30-day mortality in surgical patients, especially those undergoing coronary artery bypass grafting. However, when applied to isolated surgical aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI), it is believed to overestimate the real risk. We sought to determine whether the newly proposed EuroSCORE II scale is better calibrated with absolute risk of mortality in an unselected cohort of patients treated with TAVI.

Methods and results: The EuroSCORE and EuroSCORE II were assessed in 49 high-risk patient with aortic valve stenosis treated with TAVI from March 2010 to February 2012. The majority of cases were performed via the transfemoral route (n=36, 74%) followed by the left transsubclavian (n=8, 16%), transapical (n=3, 6%) and transaortic access (n=2, 4%). Mortality was assessed at 30 days. The study population consisted of 23 females (47%) and 26 males (53%). The mean age was 79.9±6.2 years. The expected mortality according to the EuroSCORE was 17.5% (95% confidence intervals [CI] 14.3%-20.7%), whereas in EuroSCORE II it was 5.9% (95% CI 4.2%-7.6%). After a 30-day follow-up, the observed mortality was 4.1% (two out of 49). The patients who died were only characterised by low-to-medium mortality risk in both scales (11.6% and 13.6% by EuroSCORE, 3.5% and 4.4% by EuroSCORE II).

Conclusions: EuroSCORE II more accurately predicts mean mortality in patients after TAVI. However, both current risk scores do not provide a reliable estimate of exact operative mortality in an individual patient treated with TAVI.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.88

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved